bielschowskysin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
bielschowskysin : A diterpenoid that is isolated from Pseudopterogorgia kallos and exhibits antimalarial and anticancer activity. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11201358 |
| CHEBI ID | 65497 |
| MeSH ID | M0478719 |
| Synonym |
|---|
| CHEBI:65497 |
| bielschowskysin |
| (2as,4s,4as,4bs,7s,7as,9s,10as,12r,12ar,12bs)-4,7,9-trihydroxy-4,6-dimethyl-10-methylene-1-oxo-3,4,4a,7a,9,10,10a,11,12,12b-decahydro-2ah,7h-4b,7-epoxy-2,8-dioxacyclopenta[5',6']cyclonona[2',1':1,4]cyclobuta[1,2,3-cd]pentalen-12-yl acetate |
| Q27133938 |
| bielschowskysin [mi] |
| 697298-90-1 |
| r7m3y4c8bk , |
| 7h-4b,7-epoxy-1h,3h-2,8-dioxacyclopenta(6',7')cyclonona(1',2':1,4)cyclobuta(1,2,3-cd)pentalen-1-one, 12-(acetyloxy)-2a,4,4a,7a,9,10,10a,11,12,12b-decahydro-4,7,9-trihydroxy-4,6-dimethyl-10-methylene-, (2ar,4r,4ar,4br,7r,7ar,9r,10ar,12s,12as,12br)-rel-(-)- |
Bielschowskysin is a naturally occurring diterpene isolated from the Caribbean gorgonian octocoral Pseudopterogorgia kallos.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bielschowskysin is a naturally occurring diterpene isolated from the Caribbean gorgonian octocoral Pseudopterogorgia kallos. " | ( Bielschowskysin, a gorgonian-derived biologically active diterpene with an unprecedented carbon skeleton. Baran, P; Capson, TL; Marrero, J; Ortega-Barria, E; Raptis, RG; RodrÃguez, AD; Sánchez, JA, 2004) | 3.21 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| antimalarial | A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| acetate ester | Any carboxylic ester where the carboxylic acid component is acetic acid. |
| gamma-lactone | A lactone having a five-membered lactone ring. |
| cyclic acetal | An acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring. |
| organic heterohexacyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.24) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (10.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||